Skip to content
Biophytis
LIVE HEALTHIER LONGER
Biophytis
  • Corporate
    • Executive Committee
    • Scientific Advisory Board
    • Boards of Directors
    • Code of Ethics
  • Our Science
    • BIO101
      • Posters & Publications
        • 2024
        • 2023
        • 2022
        • 2021
        • 2020
        • 2019
        • 2018
        • 2017
        • 2016
        • 2015
        • 2014
    • Macuneos (BIO201)
      • Posters & Publications
  • Pipeline
    • Pipeline
    • Key milestones in the development of BIO101
    • Sarcopenia: SARA clinical program
    • Obesity: OBA Clinical Program
    • COVID-19: COVA clinical program
    • Duchenne Muscular Dystrophy: MYODA clinical program
    • Age-related Macular Degeneration: MACA clinical program
  • Investors
    • Letter to shareholders
    • Live Stock Price
    • Corporate Presentation
    • General Meetings
      • 2024
      • 2023
      • 2022
      • 2021
      • 2020
    • AMF Regulated Information
    • SEC Filings
    • Financial Calendar
    • Convertible bonds
  • News
    • Press Releases
      • 2025
      • 2024
      • 2023
      • 2022
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
    • Biophytis in Media
  • Recruitment
  • Contact
    • Contact
    • Contact Information
    • Legal information
  • LinkedIn
  • Twitter
  • FR
  • EN
  • Corporate
    • Executive Committee
    • Scientific Advisory Board
    • Boards of Directors
    • Code of Ethics
  • Our Science
    • BIO101
      • Posters & Publications
        • 2024
        • 2023
        • 2022
        • 2021
        • 2020
        • 2019
        • 2018
        • 2017
        • 2016
        • 2015
        • 2014
    • Macuneos (BIO201)
      • Posters & Publications
  • Pipeline
    • Pipeline
    • Key milestones in the development of BIO101
    • Sarcopenia: SARA clinical program
    • Obesity: OBA Clinical Program
    • COVID-19: COVA clinical program
    • Duchenne Muscular Dystrophy: MYODA clinical program
    • Age-related Macular Degeneration: MACA clinical program
  • Investors
    • Letter to shareholders
    • Live Stock Price
    • Corporate Presentation
    • General Meetings
      • 2024
      • 2023
      • 2022
      • 2021
      • 2020
    • AMF Regulated Information
    • SEC Filings
    • Financial Calendar
    • Convertible bonds
  • News
    • Press Releases
      • 2025
      • 2024
      • 2023
      • 2022
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
    • Biophytis in Media
  • Recruitment
  • Contact
    • Contact
    • Contact Information
    • Legal information
  • LinkedIn
  • Twitter
  • FR
  • EN

Author Archives: Antoine

MAY 19, 2020

Press ReleasesBy Antoine19 May 2020

Biophytis shares resume trading following the implementation of measures ordered in connection with a dispute with NEGMA. Read the Press Release

MAY 11, 2020

Press ReleasesBy Antoine11 May 2020

Convening of another combined General Meeting at a Later Date. Read the Press Release

May 7, 2020

Press ReleasesBy Antoine7 May 2020

Biophytis shares and BSA trading is suspended pending a new press release. Read the Press Release

April 30, 2020

Press ReleasesBy Antoine30 April 2020

Biophytis AGM meeting will take place on May 11, 2020 without the physical presence of its shareholders. Read the Press Release

April 27, 2020

Press ReleasesBy Antoine27 April 2020

Biophytis Successfully Closes its Public Offering of Share Subscription Warrants (BSA). Read the Press Release

APRIL 21, 2020

Press ReleasesBy Antoine21 April 2020

Correction – Biophytis launches a Public Offering of Share Subscription Warrants (BSA) with an Irreducible Priority Subscription Period for Existing Shareholders.  Read the Press Release

April 7, 2020

Press ReleasesBy Antoine7 April 2020

Biophytis Launches COVA Clinical Study with Sarconeos (BIO101) in Covid-19. Read the Press Release

April 7, 2020

Press ReleasesBy Antoine7 April 2020

Biophytis Announces Launch of a Public Offering of Share Subscription Warrants (BSA) with an Irreducible Priority Subscription Period for Existing Shareholders. Read the Press Release

April 7, 2020

Press ReleasesBy Antoine7 April 2020

Biophytis has signed a New Convertible Bond Financing of €24 million from Atlas to Continue the Development of Sarconeos (BIO101). Read the Press Release

April 6, 2020

Press ReleasesBy Antoine6 April 2020

2019 Annual Financial Report made available. Read the Press Release

←1
234567891011121314151617
…1819202122…
232425262728293031323334
35→
© Biophytis 2006-2025 - Mentions Légales
  • Corporate
    • Executive Committee
    • Scientific Advisory Board
    • Boards of Directors
    • Code of Ethics
Footer Colonne 1 - Anglais
Go to Top
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok